Did you mean 101 19 8?
Displaying drugs 51 - 75 of 2403 in total
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Glimepiride
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive...
Approved
Matched Products: … TIDECA 8 MG TABLET, 30 TABLET ... TIDECA 8 MG TABLET, TABLET, 90 ADET …
Dalfampridine
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Sotrovimab
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Description: … sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 ... Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 ... L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 …
Matched Categories: … Approved Treatments for COVID-19 ... Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Approved Treatments for COVID-19 ... Experimental Unapproved Treatments for COVID-19 …
Chymotrypsin
Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence...
Approved
Vet approved
Beta carotene
Beta-carotene, with the molecular formula C40H56, belongs to the group of carotenoids consisting of isoprene units. The presence of long chains of conjugated double bonds donates beta-carotene with specific colors. It is the most abundant form of carotenoid and it is a precursor of the vitamin A. Beta-carotene is composed...
Approved
Nutraceutical
Matched Mixtures name: … IV-8 Formula ... Se-Natal 19 ... Thrivite 19 …
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer. It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. It is produced using recombinant DNA technology in CHO cell lines and...
Approved
Matched Description: … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein ... the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 …
Matched Categories: … COVID-19 Vaccines …
Matched Categories: … COVID-19 Vaccines …
Famtozinameran
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused …
Matched Mixtures name: … Pfizer-BioNTech Covid-19 Vaccine, Bivalent ... Pfizer-BioNTech Covid-19 Vaccine, Bivalent ... Pfizer-BioNTech Covid-19 Vaccine, Bivalent …
Matched Categories: … COVID-19 Vaccines …
Matched Mixtures name: … Pfizer-BioNTech Covid-19 Vaccine, Bivalent ... Pfizer-BioNTech Covid-19 Vaccine, Bivalent ... Pfizer-BioNTech Covid-19 Vaccine, Bivalent …
Matched Categories: … COVID-19 Vaccines …
Triamcinolone
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more...
Approved
Vet approved
Matched Salts cas: … 5611-51-8 …
Matched Products: … Volon 8 mg - Tabletten …
Matched Products: … Volon 8 mg - Tabletten …
Remoxipride
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Diiodohydroxyquinoline
Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Iupac: … 5,7-diiodoquinolin-8-ol …
Pomalidomide
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Description: … FDA approved on February 8, 2013. …
Rubidium Rb-82
Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.
Approved
Investigational
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike ... FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 ... October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike ... FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 ... October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …
Larotrectinib
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Methionine
A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Approved
Nutraceutical
Matched Mixtures name: … Numeta G 19 % E Emulsion zur Infusion ... NUMETA PED G 19 % E INFÜZYON IÇIN EMÜLSIYON, 1000 ML ... AMINOSTERIL N-HEPA 8% …
Fluconazole
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Mixtures name: … Ciclopirox 8% / Fluconazole 1% / Terbinafine HCl 1% …
Matched Products: … FLUCAN 150 MG KAPSUL, 8 ADET ... FLUZAMED 150 MG KAPSÜL ,8 KAPSÜL …
Matched Products: … FLUCAN 150 MG KAPSUL, 8 ADET ... FLUZAMED 150 MG KAPSÜL ,8 KAPSÜL …
DL-alpha tocopheryl acetate
Approved
Experimental
Matched Mixtures name: … Se-Natal 19 ... Thrivite 19 ... Se-Natal 19 …
Etanercept
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1....
Approved
Investigational
Matched Products: … ENBREL 25 MG/0,5 ML SC ENJEKSIYONLUK COZELTI İÇİN KULLANIMA HAZIR ENJEKTÖR, 8 ADET …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Iupac: … 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin …
Matched Salts cas: … 753498-25-8 …
Matched Salts cas: … 753498-25-8 …
Remdesivir
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Description: … Emergency Use Authorization on November 19, 2020. ... respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19 ... is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 …
Matched Categories: … Approved Treatments for COVID-19 …
Matched Categories: … Approved Treatments for COVID-19 …
Ceftobiprole
Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA).
The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Iupac: … (6R,7R)-7-[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(N-hydroxyimino)acetamido]-8-oxo-3-{[(3E,3'R)-2-oxo …
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Lurasidone
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Approved
Investigational
Displaying drugs 51 - 75 of 2403 in total